Different susceptibilities to 1,25-dihydroxyvitamin D3-induced differentiation of AML cells carrying various mutations

Leukemia Research

Volumn 34, Issue 5, 2010, Pages 649-657

  Gocek, Elzbieta ^a   Kiełbiński, Marek ^b   Baurska, Hanna ^a   Haus, Olga ^b,c   Kutner, Andrzej ^d   Marcinkowska, Ewa ^a  

^a UNIVERSITY OF WROC AW   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^d INDUSTRIAL CHEMISTRY RESEARCH INSTITUTE   (Poland)

Author keywords

1,25 Dihydroxyvitamin D3; Acute myeloid leukemia; Cell lines; Differentiation; Flow cytometry; Vitamin D analogs; Vitamin D receptor; Western blotting

Indexed keywords

CALCITRIOL; CALCITRIOL DERIVATIVE; CD135 ANTIGEN; VITAMIN D RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLAST CELL; CELL DIFFERENTIATION; CELL ISOLATION; CONTROLLED STUDY; CYTOGENETICS; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; GENE MUTATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS;

BLOTTING, WESTERN; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL SEPARATION; CHROMOSOMES, HUMAN, PAIR 7; FLOW CYTOMETRY; HL-60 CELLS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKEMIA, MYELOID, ACUTE; MUTATION; RECEPTORS, CALCITRIOL; VITAMIN D;

EID: 77950068062     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.10.004     Document Type: Article

References (57)

1. Hamadani M, Awan FT. Remission induction, consolidation and novel agents in development for adults with acute myeloid leukaemia. Hematol Oncol; [Epub ahead of print]. doi:10.1002/hon.915.
2. Breitman T.R., Selonick S.E., Collins S.J. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci U S A 1980, 77:2936-2940.
3. 3. Proc Natl Acad Sci U S A 1981, 78:4990-4994.
4. 3 inhibits proliferation of human promyelocytic leukaemia (HL60) cells and induces monocyte-macrophage differentiation in HL60 and normal bone marrow cells. Leuk Res 1983, 7:51-55.
5. Huang M.E., Ye Y.C., Chen S.R., Chai J.R., Lu J.X., Zhoa L., et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988, 72:567-572.
6. Luong Q.T., Koeffler H.P. Vitamin D compounds in leukemia. J Steroid Biochem Mol Biol 2005, 97:195-202.
7. 3, retinoic acid and DMSO. Leuk Res 1995, 19:57-64.
8. Sanz M.A., Grimwade D., Tallman M.S., Lowenberg B., Fenaux P., Estey E.H., et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009, 113:1875-1891.
9. Dusso A.S., Brown A.J., Slatopolsky E., Vitamin D. Am J Physiol Renal Physiol 2005, 289:F8-28.
10. Bouillion R., Okamura W., Norman A. Structure-function relationships in the vitamin D endocrine system. Endocr Rev 1995, 16:200-216.
11. Choi M., Makishima M. Therapeutic applications for novel non-hypercalcemic vitamin D receptor ligands. Expert Opin Ther Pat 2009, 19:593-606.
12. Vakirlis E., Kastanis A., Ioannides D. Calcipotriol/betamethasone dipropionate in the treatment of psoriasis vulgaris. Ther Clin Risk Manag 2008, 141-148.
13. Nuijten M., Andress D.L., Marx S.E., Sterz R. Chronic kidney disease Markov model comparing paricalcitol to calcitriol for secondary hyperparathyroidism: a US perspective. Curr Med Res Opin 2009, 25:1221-1234.
14. 3 prolong survival time of mice inoculated with myeloid leukemia cells. Proc Natl Acad Sci U S A 1983, 80:201-204.
15. 2 (a novel, noncalcemic vitamin D analogue), combined with arsenic trioxide, has potent antitumor activity against myeloid leukemia. Cancer Res 2005, 65:2488-2497.
16. 3 analogs have potent antitumor activity. J Steroid Biochem Mol Biol 2008, 112:151-156.
17. Shabtay A., Sharabani H., Barvish Z., Kafka M., Amichay D., Levy J., et al. Synergistic antileukemic activity of carnosic acid-rich rosemary extract and the 19-nor Gemini vitamin D analogue in a mouse model of systemic acute myeloid leukemia. Oncology 2008, 75:203-214.
18. Mehta A.B., Kumaran T.O., Marsh G.W., McCarthy D.M. Treatment of advanced myelodysplastic syndrome with alfacalcidol. Lancet 1984, 761.
19. 3 for prolongation of leukemic transformation-free survival in myelodysplastic syndromes. Am J Hematol 1991, 38:67-68.
20. 2 analog (Paricalcitol; Zemplar) for treatment of myelodysplastic syndrome. Leuk Res 2005, 29:1259-1262.
21. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976, 33:451-458.
22. Vardiman J.W., Harris N.L., Brunning R.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002, 100:2292-2302.
23. Studzinski G.P., Wang X., Ji Y., Wang Q., Zhang Y., Kutner A., et al. The rationale for deltanoids in therapy for myeloid leukemia: role of KSR-MAPK-C/EBP pathway. J Steroid Biochem Mol Biol 2005, 97:47-55.
24. 3. Anticancer Drugs 2007, 18:447-457.
25. Gocek E., Kiełbiński M., Marcinkowska E. Activation of intracellular signaling pathways is necessary for an increase in VDR expression and its nuclear translocation. FEBS Lett 2007, 581:1751-1757.
26. 3 activate three MAPK pathways and upregulate pRb expression in differentiating HL60 cells. Cell Cycle 2002, 1:410-415.
27. Gocek E., Kiełbiński M., Wyłób P., Kutner A., Marcinkowska E. Side-chain modified vitamin D analogs induce rapid accumulation of VDR in the cell nuclei proportionately to their differentiation-inducing potential. Steroids 2008, 73:1359-1366.
28. 3. J Steroid Biochem Mol Biol 1998, 67:71-78.
29. Morosetti R., Park D.J., Chumakov A.M., Grillier I., Shiohara M., Gombart A.F., et al. A novel, myeloid transcription factor, C/EBPepsilon, is upregulated during granulocytic, but not monocytic, differentiation. Blood 1997, 90:2591-2600.
30. Lanotte M., Martin-Thouvenin V., Najman S., Balerini P., Valensi F., Berger R. NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood 1991, 77:1080-1086.
31. Tsuchiya S., Yamabe M., Yamaguchi Y., Kobayashi Y., Konno T., Tada K. Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int J Cancer 1980, 26:171-176.
32. Sundström C., Nilsson K. Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int J Cancer 1976, 17:565-577.
33. 3-mediated stimulation of steroid sulphatase activity in myeloid leukaemic cell lines requires VDRnuc-mediated activation of the RAS/RAF/ERK-MAP kinase signalling pathway. J Cell Biochem 2006, 98:590-617.
34. Markovic A., MacKenzie K.L., Lock R.B. FLT-3: a new focus in the understanding of acute leukemia. Int J Biochem Cell Biol 2005, 37:1168-1172.
35. Stirewalt D.L., Radich J.P. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer 2003, 3:650-665.
36. Choudhary C., Schwäble J., Brandts C., Tickenbrock L., Sargin B., Kindler T., et al. AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations. Blood 2005, 106:265-273.
37. 3. Br J Haematol 2001, 112:315-326.
38. Swerdlow S.H., Campo E., Harris N.L., Jaffe E.S., Pileri S.A., Stein H., et al. Tumours of haematopoietic and lymphoid tissues (World Health Organization classification of tumours) 2008, International Agency for Research on Cancer, p. 109-38. 7th ed.
39. Meshinchi S., Woods W.G., Stirewalt D.L., Sweetser D.A., Buckley J.D., Tjoa T.K., et al. Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood 2001, 97:89-94.
40. Rosnet O., Birnbaum D. Hematopoietic receptors of class III receptor-type tyrosine kinases. Crit Rev Oncog 1993, 4:595-613.
41. Zeng H., Masuko M., Jin L., Neff T., Otto K.G., Blau C.A. Receptor specificity in the self-renewal and differentiation of primary multipotential hemopoietic cells. Blood 2001, 98:328-334.
42. McKenna H.J., Stocking K.L., Miller R.E., Brasel K., De Smedt T., Maraskovsky E., et al. Mice lacking Flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood 2000, 95:3489-3497.
43. Yokota S., Kiyoi H., Nakao M., Iwai T., Misawa S., Okuda T., et al. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia 1997, 11:1605-1609.
44. Callens C., Chevret S., Cayuela J.M., Cassinat B., Raffoux E., de Botton S., et al. Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group. Leukemia 2005, 19:1153-1160.
45. Yamamoto Y., Kiyoi H., Nakano Y., Suzuki R., Kodera Y., Miyawaki S., et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001, 97:2434-2439.
46. Taketani T., Taki T., Sugita K., Furuichi Y., Ishii E., Hanada R., et al. FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy. Blood 2004, 103:1085-1088.
47. Christiansen D.H., Andersen M.K., Pedersen-Bjergaard J. Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation. Blood 2004, 104:1474-1481.
48. Michaud J., Scott H.S., Escher R. AML1 interconnected pathways of leukemogenesis. Cancer Invest 2003, 21:105-136.
49. Roumier C., Fenaux P., Lafage M., Imbert M., Eclache V., Preudhomme C. New mechanisms of AML1 gene alteration in hematological malignancies. Leukemia 2003, 17:9-16.
50. Zhang J., Liu Z., Shao H., Ma Y., Tong H., Wang Y. Laboratory study of a complex translocation t(2;8;21) (p12;q22;q22) in a patient with acute myelogenous leukemia. Leuk Lymphoma 2008, 49:1925-1928.
51. Perkins D., Brennan S., Carstairs K., Bailey D., Pantalony D., Poon A., et al. Regional cancer cytogenetics: a report on 1,143 diagnostic cases. Cancer Genet Cytogenet 1997, 96:64-80.
52. Brozek I., Babińska M., Kardaś I., Woźniak A., Balcerska A., Hellmann A., et al. Cytogenetic analysis and clinical significance of chromosome 7 aberrations in acute leukaemia. J Appl Genet 2003, 44:401-412.
53. El-Rifai W., Elonen E., Larramendy M., Ruutu T., Knuutila S. Chromosomal breakpoints and changes in DNA copy number in refractory acute myeloid leukemia. Leukemia 1997, 11:958-963.
54. Johansson B., Mertens F., Mitelman F. Cytogenetic deletion maps of hematologic neoplasms: circumstantial evidence for tumor suppressor loci. Genes Chromosomes Cancer 1993, 8:205-218.
55. McKenna R.W. Multifaceted approach to the diagnosis and classification of acute leukemias. Clin Chem 2000, 46:1252-1259.
56. Marquez Balbas G., Sanchez Regana M., Umbert Millet P. Tacalcitol ointment for the treatment of nail psoriasis. J Dermatol Treat 2009, 1:1-3.
57. Rodríguez-Martín M., García Bustínduy M., Sáez Rodríguez M., Noda Cabrera A. Randomized, double-blind clinical trial to evaluate the efficacy of topical tacalcitol and sunlight exposure in the treatment of adult nonsegmental vitiligo. Br J Dermatol 2009, 160:409-414.